Amgen Settles On Bevacizumab And Trastuzumab
Genentech Had Failed To Enjoin Sales Of Biosimilars In US
Amgen has filed to settle on undisclosed terms patent-infringement litigation involving both its Kanjinti and Mvasi biosimilars, having previously seen originator Genentech fail multiple times to block commercial sales of the products that were launched ‘at risk’.
